Abstract
Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Adiponectin / blood
-
Biomarkers / blood
-
Blood Glucose / drug effects*
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Glycated Hemoglobin / metabolism*
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Meta-Analysis as Topic
-
Peroxisome Proliferator-Activated Receptors / agonists
-
Predictive Value of Tests
-
Reproducibility of Results
-
Time Factors
-
Translational Research, Biomedical*
-
Treatment Outcome
Substances
-
ADIPOQ protein, human
-
Adiponectin
-
Biomarkers
-
Blood Glucose
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Peroxisome Proliferator-Activated Receptors
-
hemoglobin A1c protein, human